Suggestions
Julien A. Grant
Corporate Development and Strategy Executive
Julien Grant is a proven hands-on operator with extensive experience in leading cross-functional teams and driving business performance. He has successfully grown revenue over $350M per year through active portfolio management and has a significant background in end-to-end deal execution, with over $3B in BOD deal approval and $1.8B in executed deals. Julien has a reputation as a motivational leader who attracts people from across disciplines and business units to collaborate on a high-performing team.
Julien has a bachelor's in aerospace engineering from the US Naval Academy and served as a naval officer in several countries, including Italy, Germany, and Panama, and in the Desert Shield Operation in the Persian Gulf. He earned his MBA from Northwestern University - Kellogg School of Management and worked in international banking (London and Zurich, Goldman Sachs) before moving to finance and mergers & acquisitions (McData, MWH, Covidien).
He has held several senior-level positions, including Senior Director Corporate Development at Thermo Fisher Scientific, Head Of Corporate Development at Consultant, and Senior Director, Corporate Strategy and Portfolio Management at Medtronic. Julien also served as the Global Director, Business Development and Licensing (M&A) at Covidien and was the Senior Director of Corporate Strategy at Covidien (Medtronic Minimally Invasive Therapies Group). Most recently, he worked as the Vice President, Business Development at Philips Sleep and Respiratory Care and is currently the Senior Director, International Expansion Strategy at Insulet Corporation.
Julien's diverse background makes him a master at proposing practices for allocating resources across industries. He gained a reputation for applying analytical frameworks to aid complex decision-making, something he further applied in strategy and portfolio management. Overall, he is an expert in corporate strategy, portfolio management, business development, mergers & acquisitions, and finance.